All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
The GvHD Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
The GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Abatacept as a novel agent for the treatment of steroid-refractory cGvHD: A phase II trial
The results of a phase II clinical trial of abatacept for steroid-refractory chronic graft-versus-host disease (cGvHD) were presented by Anita Koshy1 at the...
Jun 13, 2022
|TCT 2022
Mohamad Mohty
"The new GvHD Hub is an amazing resource for physicians and healthcare professionals in the field of GvHD. We have recently seen some great advances in this era, and the GvHD Hub is the place to go for the most up-to-date information."
Are you a healthcare professional? What is your speciality?
Please select or type your speciality
By sharing this information, you can help ensure we continue to develop content that is of most relevance for our audience.
Thank you for submitting.